Clinical trials: Diabetic Kidney Disease
Diabetes Mellitus, Type 1, Diabetic Nephropathy
Matrix Metalloproteinases and Diabetic Nephropathy
Matrix metalloproteinases (MMPs) are a family of protein-degrading enzymes that are involved in the breakdown and remodeling of many tissues and organs.
- Trial name
- NCT00067886
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Arkansas Children's Hospital Research Institute
Diabetic Kidney Disease
The Phase I Clinical Study to Evaluate the Pharmacokinetics of Dw1029M in Healthy Male Volunteer
1. Objective After single dose in healthy adults the capacity of the Group for DW1029M evaluate the pharmacokinetic characteristics. 2. Indication Diabetic kidney disease 3. Efficacy 1.
- Trial name
- NCT02004327
- Testing
- DW1029M300mg, DW1029M600mg, DW1029M1200mg
- Where
- South Korea
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Sleep Apnea, Diabetic Nephropathy Type 2
Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
Background: Diabetes, and especially diabetic kidney disease is associated with the development of cardiovascular disease such as calcification in the coronary arteries and heart failure.
- Conditions
- Sleep Apnea, Diabetic Nephropathy Type 2, Coronary Atheroscleroses, Heart Insufficiency
- Trial name
- SLEEP (NCT04549324)
- Where
- Denmark
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Nephropathy, Hypoxia
Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes
Background: Inhibiting the sodium-glucose cotransporter-2 (SGLT2) has been observed to reduce risk of cardiovascular events and kidney failure in type 2 diabetes.
- Conditions
- Nephropathy, Hypoxia, Mitochondrial Alteration, Type 1 Diabetes
- Trial name
- Astronaut (NCT04193566)
- Testing
- Forxiga
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Steno Diabetes Center Copenhagen
Healthy Adult Participants, Diabetic Kidney Disease
Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease
This is a phase 1 randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and Pharmacokinetics (PK) of single and multiple ascending doses of MTX-439…
- Trial name
- NCT07473323
- Testing
- MTX-439
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Mediar Therapeutics
Type 2 Diabetes
Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease
The purpose of the study is to investigate the effect of a blood pressure medication, Lisinopril, or similar drugs in that class, on the flow of blood to the kidneys.
- Trial name
- NCT01101269
- Testing
- ACEI or ARB, Lisinopril
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Endometriosis Related Pain, Overactive Bladder
Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function
BAY1817080 is currently under clinical development to treat pain related to unexplained chronic cough or chronic cough not affected by a treatment (refractory and/or unexplained chronic cough, RUCC), or a condition where the…
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04471337
- Testing
- BAY1817080
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Non-diabetic Chronic Kidney Disease, Atherosclerosis
Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease
The aim of the study is to evaluate whether a low level of serum omentin-1 is associated with carotid atherosclerosis and mediated by inflammation.
- Trial name
- NCT01701830
- Where
- Turkey (Türkiye)
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Kocaeli Derince Education and Research Hospital
Contrast-induced Nephropathy
Role of Amlodipine in Reduction of CIN
The aim is to assess the benefit of low dose oral amlodipine in renal protection from contrast induced nephropathy in diabetic patients in intensive care unit
- Trial name
- NCT07291375
- Testing
- Calcium channel blocker, Hydration
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Minia University
Diabetic Nephropathy Type 2
Relationship Between Serum N/OFQ and Type 2 Diabetic Nephropathy
At present, the early diagnosis ability of diabetic nephropathy (DKD) is relatively poor, leading to some missed diagnosis of early disease patients.
- Trial name
- NCT04962399
- Testing
- Enzyme linked immunosorbent assay
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Zheng Guo
Urine VOCs From DKD and Nephrotic Syndrome Pateints
The Biosensor Using the Target Urine VOCs for Detecting DKD Diabetic Kidney Disease
Volatile organic compounds (VOCs) are easily evaporated substances produced by pathophysiologic metabolism and have been utilized in research as potential new biomarkers for differentiating various diseases, acting as the odor…
- Trial name
- VOCs in DKD (NCT07137351)
- Testing
- The Biosensor Using the Target Urine Volatile Organic Compounds
- Where
- Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- Suranaree University of Technology
End-stage Kidney Disease, Diabetes Mellitus
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula
Background Arteriovenous (AV) fistula is the most common vascular access for long-term hemodialysis in the end-stage renal disease (ESRD) patients. About 25% of these patients are diabetes mellitus.
- Conditions
- End-stage Kidney Disease, Diabetes Mellitus, Arteriovenous Fistula
- Trial name
- NCT01863914
- Testing
- Rosuvastatin
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Cheng-Kung University Hospital
Diabetic Nephropathies
MRI Biomarkers in Diabetic Kidney Disease
Diabetic kidney disease is one of the most severe and frequent complications of diabetes. Few preclinical markers are available apart from plasma creatinine and microalbuminuria.
- Trial name
- MR3T - DKD (NCT04570735)
- Testing
- MRI
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Poitiers University Hospital
Renal Insufficiency, Healthy
A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function
The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of canagliflozin (JNJ-28431754) after administration of a single dose to…
- Trial name
- NCT01759576
- Testing
- Canagliflozin (JNJ-28431754)
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Kidney Diseases
Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients
Chronic kidney disease (CKD) is a common disease affecting 10-12% of the adult population and characterize with high-risk cardiovascular morbidity and mortality with progression of CKD.
- Trial name
- DAPA-GUT (NCT05965440)
- Testing
- impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Diabetic Nephropathy, Hypertension
Angiotensin II Antagonism of TGF-Beta 1
Diabetic nephropathy is a frequent microvascular complication that occurs in approximately 40% of patients with either type 1 or type 2 diabetes.
- Trial name
- NCT00320970
- Testing
- Candesartan
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Providence Health & Services
Diabetic Foot, Type 2 Diabetes Mellitus With Established Diabetic Nephropathy
The Effectiveness of Improving Self-care After Counseling for the Diabetics Mellitus Foots Around Chiayi Region
Objectives: Preventing diabetic foot problems (DFP) and associated consequences, such as amputation, is a critical in rural regions.
- Trial name
- NCT01299246
- Testing
- Michigan Neuropathy Screening Instrument
- Where
- Taiwan
- Volunteers
- 386 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Diabetic Nephropathy
Assessment of Urinary Uromodulin and the Corresponding Gene Expression as a Biomarker of Diabetic Nephropathy
Detecting diabetes-related kidney diseases early is crucial to prevent end-stage renal disease (ESRD). Existing biomarkers' specificity and sensitivity vary, emphasizing the need for novel markers.
- Trial name
- NCT05695573
- Testing
- ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tanta University
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.
Current study will render insight in to the role of renal hypoxia in the diabetic kidney and is able to associate its finding with measurements of renal perfusion and glomerular filtration rate.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Diabetic Nephropathy, Renal Hypoxia
- Trial name
- ROCKIES (NCT04027530)
- Testing
- Ertugliflozin 15 mg
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Diabetic Nephropathy
The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
1. To evaluate expression levels of circANKRD36 in the development and progression of DN. 2. To investigate correlation between expression levels of circANKRD36 and stages of DN. 3.
- Trial name
- NCT05061459
- Testing
- circANKRD36 as a new biomarker
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Assiut University